PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
STCube is expanding multinational trials of nelmastobart, targeting the self-discovered immune checkpoint BTN1A1, in colorectal cancer and NSCLC while pursuing a two-track global-and-China licensing strategy, even as revenue remains minimal and large capital raises continue.
Nelmastobart is a first-in-class candidate targeting BTN1A1, an immune checkpoint protein the company says it first identified.
Phase 2 trials in metastatic colorectal cancer (STCUBE-003) and NSCLC (STCUBE-004) are running in parallel, while a China-specific Phase 1b trial has begun through a local partner.
2025 revenue fell to roughly KRW 7.0 billion from KRW 11.3 billion in 2024, while operating losses persisted in the KRW 18–26 billion range across all four years.
Over the trailing four quarters (2025Q3–2026Q2), net loss totaled about KRW 24.0 billion, with the quarterly loss peaking in Q1 2026 before narrowing slightly in Q2.
STCube carried out a large third-party and shareholder-priority rights offering to address managed-issue concerns and secure clinical funding, a process that is set to change its controlling shareholder.
STCube's core business is immuno-oncology drug development, complemented by a cosmetics brand called Signal's and a distribution business for industrial lens modules sourced from China and Japan.
Its lead drug candidate, nelmastobart (code name hSTC810), targets BTN1A1, a novel immune checkpoint protein the company says it discovered, and is positioned to reach patients who do not respond to existing PD-1/PD-L1 therapies because of its mutually exclusive expression pattern.
Domestically, the company is running a Phase 1b/2 trial in metastatic colorectal cancer (STCUBE-003) and a Phase 2 trial in advanced/metastatic NSCLC (STCUBE-004), with the NSCLC trial combining nelmastobart with docetaxel in patients with high BTN1A1 expression (tumor proportion score of 50% or higher).
In China, an affiliate of the controlling shareholder, STCube & Company, has initiated a Phase 1b colorectal cancer trial through local partner Beijing Weilifang, which is bearing the trial costs while STCube supplies the drug product.
The cosmetics segment has shown growth through overseas expansion of the Signal's brand and influencer marketing, while the IT distribution segment generates stable revenue from lens module sales. Both non-drug segments help supplement cash flow needed for drug development.
Competitively, nelmastobart remains pre-commercial and is positioned to complement rather than directly rival established PD-1/PD-L1 franchises by targeting patients who have failed those therapies.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩900M | -₩5.5B | −588.2% |
| 2025Q3 | ₩1.5B | -₩5.8B | −387.7% |
| 2025Q4 | ₩2.7B | -₩7B | −254.9% |
| 2026Q1 | ₩1.4B | -₩7.3B | −536.1% |
| 2026Q2 | ₩1.5B | -₩6.1B | −403.3% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩6.3B | -₩18.9B | -₩18.9B | −300.1% | −36.9% | 19.2% |
| 2023 | ₩5.8B | -₩26B | -₩24.5B | −446.9% | −69.4% | 30.2% |
| 2024 | ₩11.3B | -₩22.6B | -₩21.4B | −200.2% | −22.7% | 18.7% |
| 2025 | ₩7B | -₩23.5B | -₩21.8B | −336.1% | −30.2% | 25.1% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04
Annual revenue moved without a clear growth trend: KRW 6.30 billion in 2022, KRW 5.83 billion in 2023, KRW 11.30 billion in 2024, and KRW 6.98 billion in 2025.
Operating losses stayed in the KRW 18–26 billion range throughout, worsening to an operating margin of -446.9% in 2023, improving to -200.2% in 2024, and widening again to -336.1% in 2025.
Net loss attributable to owners also stayed in a KRW 18.9–24.5 billion band across all four years, showing no clear improvement trend yet.
On a quarterly basis, net loss widened from KRW 5.43 billion in Q2 2025 to KRW 6.56 billion in Q4 2025, peaked at KRW 6.75 billion in Q1 2026, and then narrowed to KRW 5.53 billion in Q2 2026.
Operating loss similarly eased from KRW 7.31 billion in Q1 2026 to KRW 6.06 billion in Q2 2026, a pattern that coincides with the timing of initial clinical spending for the newly launched NSCLC trial.
Equity fell from KRW 51.2 billion in 2022 to KRW 35.3 billion in 2023, rebounded to KRW 94.3 billion in 2024 after two rights offerings, and declined again to KRW 72.1 billion in 2025 as accumulated losses ate into capital.
Operating cash flow was negative by KRW 16–25 billion in every year shown, underscoring that clinical and R&D spending has not been offset by revenue. The debt ratio has stayed contained between 18.7% and 30.2%, reflecting low reliance on borrowed capital, though that has come at the cost of repeated equity dilution.
The immuno-oncology market has entered a mature cycle in which PD-1/PD-L1 therapies are already established blockbusters, making the discovery of next-generation checkpoint targets for patients who fail to respond to or relapse on these therapies a central industry challenge.
According to domestic reporting, the unmet-need market tied to PD-L1 failure is estimated to reach USD 69–79 billion by 2029, suggesting commercial opportunity remains for newcomers built around novel targets such as BTN1A1.
Multiple Korean biotech companies, including GI Innovation, Lunit, Vaxcell-Bio, and SillaJen, are unveiling clinical data at global conferences such as ASCO and AACR in pursuit of large licensing deals, placing nelmastobart within this broader wave of Korean biotech out-licensing activity.
ASCO, one of the world's three major oncology conferences, centers on human clinical data, and observers note that compelling results there can translate into actual licensing outcomes.
Still, nelmastobart and many comparable BTN1A1 or next-generation checkpoint candidates remain at Phase 2 or earlier, making it difficult to conclude that any single program holds a decisive lead in trial progress.
China is cited as a market requiring a distinct clinical and regulatory strategy, with safety data gathered through local partners seen as a factor that could strengthen future licensing negotiations there.
The company is sequentially unveiling nelmastobart data across a series of 2026 global conferences while continuing licensing discussions.
At AACR in April it presented multi-biomarker analysis in colorectal cancer tissue and preclinical combination data in NSCLC, and at ASCO in May it presented multiplex immunohistochemistry analysis from the Phase 1b/2 colorectal trial along with early Phase 2 cohort data.
In June it attended BIO USA 2026 in San Diego, pitching a "two-track business development" strategy that separates global and China rights while holding partnering discussions with global pharmaceutical companies.
The CEO stated there that China licensing discussions have progressed, supported by the ongoing local Phase 1b trial.
This month (September 2026), the World Conference on Lung Cancer (WCLC 2026) in Seoul is scheduled to feature initial results from the NSCLC Phase 2 trial (STCUBE-004), an opportunity to gauge potential improvement over docetaxel.
The company has also indicated plans to begin basket trials in the second half of 2026 covering esophageal, head and neck, liver, and gastric cancers.
Separately, to resolve the pre-tax loss-to-equity ratio issue that triggered its managed-issue designation, STCube carried out a large rights offering that will change its controlling shareholder to STCube & Company.
However, since the raised funds are earmarked entirely for clinical and R&D spending, substantial cash consumption is likely to continue.
Because the company remains in a net loss position, earnings-based valuation multiples are difficult to compute, and the shares tend to trade at a substantial premium to net asset value. There is no history of dividend payments, making yield-based comparisons of limited use.
Given that revenue has fluctuated without a clear growth trend across multiple years and loss levels have persisted without a definitive narrowing pattern, the current valuation appears to reflect market expectations tied to nelmastobart's clinical data and licensing prospects more than realized financial performance.
Equity capital has expanded and contracted repeatedly through successive rights offerings, a pattern tied to the financing cycle typical of clinical-stage drug developers. Market interpretation of the valuation is likely to shift each time new clinical data or licensing news is confirmed going forward.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04
Nelmastobart targets BTN1A1, an immune checkpoint the company says it was first to identify, with a mutually exclusive expression pattern versus PD-1/PD-L1. This allows it to target a distinct unmet-need population of patients who failed existing immunotherapies. Reporting places this related market at USD 69–79 billion by 2029, indicating meaningful underlying demand.
Phase 2 trials in colorectal cancer and NSCLC are running domestically in parallel, while a China Phase 1b trial has started through a separate local partner.
In 2026 the company has sequentially presented data at major conferences including AACR, ASCO, BIO USA, and WCLC while pursuing two-track global and China licensing talks. Continued conference presentations may broaden the pool of potential partnering contacts.
STCube carried out a large rights offering aimed at resolving the cause of its managed-issue designation and securing clinical funding.
This raises equity, lowering the risk of re-designation as a managed issue, and provides funding for the colorectal cancer and NSCLC trials as well as basket trials planned for the second half of 2026.
2025 revenue fell to KRW 6.98 billion from KRW 11.3 billion in 2024, and operating losses stayed in the KRW 18–26 billion range in every year shown. Most revenue comes from non-core cosmetics and IT distribution businesses, meaning the drug segment itself has no commercial revenue yet.
The company conducted large third-party and shareholder-priority rights offerings twice in 2024 and again in 2026, with the controlling shareholder changing multiple times in the process. Equity swung from KRW 35.3 billion in 2023 to KRW 94.3 billion in 2024 and back down to KRW 72.1 billion in 2025. Continued clinical spending could lead to further capital raises and dilution.
While the company has stated it is holding discussions with global and China partners at multiple conferences, no specific deal timing or terms have been disclosed.
Most trials remain at Phase 2, so if data falls short of expectations or negotiations are delayed, cash consumption could continue to outpace any deal progress.
Operating cash flow was negative by KRW 16–25 billion in every year shown, reflecting a structure in which revenue cannot cover clinical spending.
The recent large rights offering has bolstered near-term funds, but since the entire proceeds are earmarked for clinical and R&D use, the need for further capital raises could resurface over the medium term.
The company was designated a KOSDAQ managed issue in March 2024 due to its pre-tax loss-to-equity ratio. The recent rights offering has strengthened equity and reduced the risk of re-designation, but if large losses continue, a similar financial-requirement issue could recur.
Nelmastobart is at Phase 2 in both colorectal cancer and NSCLC, leaving multiple hurdles before any final approval. The China trial depends on the pace and regulatory environment managed by a local partner, so timelines could shift based on that partner's circumstances.
The World Conference on Lung Cancer (WCLC 2026) in Seoul is scheduled to feature initial results from the NSCLC Phase 2 trial (STCUBE-004), an opportunity to assess response improvement versus docetaxel.
Watch for whether and when STCube initiates the planned nelmastobart basket trials covering esophageal, head and neck, liver, and gastric cancers.
Third-quarter disclosures will be a checkpoint to gauge the pace of clinical spending, cash burn trends, and revenue swings in the cosmetics and IT distribution segments.
Continue monitoring for disclosures on the progress of the China Phase 1b trial and any licensing negotiation outcomes through the local partner.
STCube is expanding domestic and international trials of nelmastobart, its lead candidate targeting the self-discovered checkpoint BTN1A1, in colorectal cancer and NSCLC, while unveiling data at multiple 2026 global conferences to advance licensing discussions.
However, four years of financial statements show operating losses persisting in the tens of billions of won without clear revenue growth, funding has come through repeated large rights offerings, and the controlling shareholder is set to change as a result.
The company's past managed-issue designation and recent capital raise reduce near-term financial risk, but since the proceeds are earmarked entirely for clinical use, meaningful cash consumption is likely to continue.
Trials remain at Phase 2, leaving time and uncertainty before any commercialization or licensing deal materializes. For observers, the key checkpoints ahead are the upcoming WCLC presentation, the planned second-half basket trial initiation, and progress on the China trial and licensing negotiations.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.